WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
How Diddy made himself the 'victim' in apology video where he does not mention ex
Beijing Rolls out Measures to Boost Consumption
AI empowers traditional Chinese medicine to explore new potentials
Mohammad Mokhber: Who is Iran’s acting president?
(HKSAR 25) Hong Kong's Future Very Promising: Chief Executive Carrie Lam
Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
China Sees Wider High School Education Coverage